We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
OPKO Health Inc is a diagnostics & research business with stocks listed in the US. OPKO Health shares (OPK) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$4.53 – a decrease of 1.31% over the previous week. Here's how to invest if you're based in Australia.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Long-term investing
| 52-week range | US$3.26 - US$6.27 |
|---|---|
| 50-day moving average | US$4.2984 |
| 200-day moving average | US$3.9278 |
| Target price | US$6.7 |
| PE ratio | 38.3898 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | US$0.118 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $4.53
| 1 week (2022-01-12) | 2.03% |
|---|---|
| 1 month (2021-12-17) | 2.72% |
| 3 months (2021-10-19) | 20.80% |
| 6 months (2021-07-19) | 28.33% |
| 1 year (2021-01-19) | -0.22% |
|---|---|
| 2 years (2020-01-17) | 190.38% |
| 3 years (2019-01-18) | 19.21% |
| 5 years (2017-01-19) | -48.23% |
Valuing OPKO Health stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of OPKO Health's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
OPKO Health's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 38x. In other words, OPKO Health shares trade at around 38x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
OPKO Health's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$178.6 million (£0.0 million).
The EBITDA is a measure of a OPKO Health's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | US$1.9 billion |
|---|---|
| Operating margin TTM | 5.3% |
| Gross profit TTM | US$465.7 million |
| Return on assets TTM | 2.58% |
| Return on equity TTM | 4.48% |
| Profit margin | 4.06% |
| Book value | 2.591 |
| Market capitalisation | US$3.1 billion |
TTM: trailing 12 months
We're not expecting OPKO Health to pay a dividend over the next 12 months.
Over the last 12 months, OPKO Health's shares have ranged in value from as little as US$3.26 up to US$6.27. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while OPKO Health's is 1.7319. This would suggest that OPKO Health's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units, as well as 4Kscore prostate cancer testing services. The company's Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. It also specialty active pharmaceutical ingredients; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.
Don't fall for the scam artists when you're trying to protect your health - here's what to check.
Here's where you can book COVID-19 at-home tests approved for travel and how they work.
We've rounded up everything you need to nail the 'date-worthy' makeup look, including some affordable dupes.
Designed for big companies, this Amex charge card offers a mix of management tools and perks – including a 100,000 bonus Membership Rewards offer.
Rapid antigen tests are proving extremely hard to find, but there are options if you can be patient trying to find a RAT.
We tried the viral Milk Makeup Hydro Grip Primer and spoiler alert, it's the bee's knees.
Drac and the Pack are back, like you’ve never seen them before.
A delightful compact vacuum with an unjustifiable price.
A new player enters the Australian sports broadcast market.
The Amazon Echo Buds 2 are a solid addition to your earholes if you’re already integrated in the Alexa ecosystem. But if you’re not, its hard to find anything here that really stands out.
